A slap in the Pface: Big Pharma CEO: C19 will be a ‘multi-billion $ franchise for years to come’

A slap in the Pface: Pfizer chief: Covid will be a ‘multi-billion $ franchise for years to come’

Firm prepares to stick 10,000% Markup on its Vaccine

Daily Mail

  • The price hike is a result of dwinding government funds for vaccine doses 
  • The uninsured population will be on the hook for the out of pocket cost of shots
  • Pfizer has earned about $80bn on vaccines and the antiviral drug Paxlovid 

Pfizer’s chief financial officer has described the Covid pandemic as a ‘multi-billion dollar franchise’ — and expects profit to continue.

David Denton told investors in an earnings call last week his company’s vaccine and antiviral would still be ‘relevant for many years to come’.

The CFO said he expects the Covid virus to be ‘somewhat like a flu… but more deadly’ — meaning therapeutics will still have a massive role in controlling the virus.

So far Pfizer has reaped about $80 billion in yearly revenue from sales of Covid vaccines and the antiviral drug Paxlovid.

The company announced last month it will triple the price of its shot to up to $130 per dose next year — a far cry from the roughly $19 to $30 per dose that the government paid.

Some experts estimate each individual shot to cost just $1.18 to make — meaning the new price represents a 10,000 per cent markup.

Analysts speculate that the move was made so Pfizer could still meet its target of $32 billion of projected vaccine revenue this year.

Critics say that the decision shows the firm’s greed. Peter Maybarduk, director of access to medicines at Public Citizen, told DailyMail.com that the firm was already in a good of financial position that they could take some loss.

Maybarduk also said that the firm has already made an ‘obscene’ amount of money, and will be ok if they do not meet revenue projections that were likely inflated anyways.

Pfizer was an early winner during the pandemic when it became the first company to get a Covid-19 vaccine approved for the US market. Subsequent vaccine mandates for healthcare workers and the military further drove up sales of vaccines.

The company projects $102 billion in total revenue this year with the vaccine and its antiviral  Paxlovid – more than double the company’s yearly revenue in 2019 ($40.9 billion) and 2020 ($41.7 billion).


Pfizer CEO Albert Bourla told investors last Tuesday: ‘With regard to our COVID-19 products, while their sales may fall from our expected 2022 levels of approximately combined $55 billion, we believe our COVID-19 franchises will remain multibillion-dollar revenue generators for the foreseeable future…


The company also expects its vaccines in development for respiratory syncitial virus to be a big earner once it earns regulatory approval. The company is working on shots to help seniors who are at higher risk of contracting the disease as well as pregnant women who, when given the shots, confer some protection to their babies in utero.

Bourla said: ‘So there is the potential that, subject to regulatory approval, by late 2023, early 2024, we could have the only RSV maternal vaccine in the market, along with an RSV vaccine for older adults.’

‘Combined, the 2 indications represent a potential multibillion-dollar peak revenue opportunity if approved, especially with our highly respected primary care sales force executing these launches,’ he added.

Read complete orginal article from Daily Mail…

Header featured image (edited) credit: Med Tech holding vile/REUTERS Image

Emphasis and pictorial image added by (TLB) editors



Stay tuned to …


The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)


Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.


Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.


Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.

Be the first to comment

Leave a Reply

Your email address will not be published.